

## Resignation of Chief Executive Officer

---

**13 September 2022 - AusCann Group Holdings Limited** (ASX: AC8) ('AusCann' or 'the Company') announce the resignation of its Chief Executive Officer, Mr Layton Mills. Mr Mills, who has been with the Company for one and half years, will continue to support the Company during the remainder of his 6 month notice period, before pursuing other business interests.

Mr Mills has been integral to the continued progress of the Company's animal health pipeline, following the acquisition of CannPal Animal Therapeutics.

Chief Executive Officer of AusCann, Mr. Layton Mills, said "I am thankful for the opportunity given to me by the Board and shareholders of AusCann during the last 18 months, and would like to personally thank the AusCann Board for their support. I look forward to following the Company's journey."

AusCann Chair, Mr. Tod McGrouther said "We would like to thank Layton for his efforts since AusCann acquired CannPal and wish him well in his future endeavours. The Board will work closely with Layton to manage the transition throughout the end of the year with a view to appointing a new CEO at the appropriate time."

AusCann also refers to its announcement of 9 September 2022, 'Increase to EuroCann Facility & Sale of Wangara Premises.' The Company notes the references in that announcement to its previous announcement of '29 August 2022' should instead refer to its previous announcement of '29 April 2022'.

### ENDS

This ASX announcement was authorised for release by the Board of AusCann.

#### For more information, please contact:

Tod McGrouther  
Chair  
info@auscann.com.au  
+61 8 6444 1720

#### ABOUT AUSCANN

**AusCann Group Holdings Limited** (ASX:AC8) is an Australian-based company focused on the development and commercialisation of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Our key difference is the commitment to rigorous product development, focused on providing reliable, stable and standardised cannabinoid-derived therapeutics products, whilst generating robust safety, quality assurance and efficacy data to support market access in various regulatory environments around the world.